fashion -WSS

fashion

author：comprehensive 2025-09-30 17:27:48 - browse：27946

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

WSS

How to use technology to prevent future drug shortages

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Hospitals owned by private equity see complications spike 25%

How to use technology to prevent future drug shortages

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

NIH trials fail to test meaningful long Covid therapies, experts say

focus

fashion

hotspot

Supreme Court strikes down use of affirmative action

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Drug repurposing or repositioning? The language matters

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

State Dept. review finds Biden bears some blame for Afghanistan failures

HCA sued by state AG for quality issues at Mission Health

What does generative AI mean for health care? We asked experts

Virtual care provider acquires bankrupt Pear's prescription apps

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Hospitals owned by private equity see complications spike 25%

focus

Virtual care provider acquires bankrupt Pear's prescription apps

Police still searching for prisoner who escaped from NYC hospital

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

How to keep neuroscience’s past racism from being its future

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

hotspot

knowledge

entertainment

entertainment